| Target Price | $81.60 |
| Price | $67.21 |
| Potential |
21.41%
register free of charge
|
| Number of Estimates | 28 |
|
28 Analysts have issued a price target CRISPR Therapeutics AG 2026 .
The average CRISPR Therapeutics AG target price is $81.60.
This is
21.41%
register free of charge
$281.40
318.69%
register free of charge
$32.32
51.91%
register free of charge
|
|
| A rating was issued by 36 analysts: 22 Analysts recommend CRISPR Therapeutics AG to buy, 13 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the CRISPR Therapeutics AG stock has an average upside potential 2026 of
21.41%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 37.31 | 29.58 |
| 89.95% | 20.72% | |
| EBITDA Margin | -1,198.90% | -1,935.91% |
| 2,095.58% | 61.47% | |
| Net Margin | -981.64% | -1,890.83% |
| 2,272.21% | 92.62% |
29 Analysts have issued a sales forecast CRISPR Therapeutics AG 2025 . The average CRISPR Therapeutics AG sales estimate is
This results in the following potential growth metrics:
11 Analysts have issued an CRISPR Therapeutics AG EBITDA forecast 2025. The average CRISPR Therapeutics AG EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
32 CRISPR Therapeutics AG Analysts have issued a net profit forecast 2025. The average CRISPR Therapeutics AG net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -4.34 | -6.33 |
| 123.71% | 45.85% | |
| P/E | negative | |
| EV/Sales | 148.47 |
32 Analysts have issued a CRISPR Therapeutics AG forecast for earnings per share. The average CRISPR Therapeutics AG EPS is
This results in the following potential growth metrics and future valuations:
CRISPR Therapeutics AG...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| B of A Securities |
Locked
➜
Locked
|
Locked | Oct 17 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Oct 10 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 23 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Sep 18 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 07 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Aug 06 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Aug 05 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
B of A Securities:
Locked
➜
Locked
|
Oct 17 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Oct 10 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 23 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Sep 18 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 07 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Aug 06 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Aug 05 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


